Norditropin should not be used in patients with known hypersensitivity to somatropin or any of its excipients.
Norditropin不应用于已知对生长激素或其中任何辅料过敏的患者。
Patients with preexisting diabetes or glucose intolerance should be monitored closely during somatropin therapy.
患糖尿病或葡萄糖耐受不良的患者，在生长激素治疗期间应严密监测。
Blood glucose levels should be monitored periodically as treatment with somatropin may decrease insulin sensitivity.
生长激素能降低胰岛素的敏感性，因此应周期性监测血糖水平。
The study results suggest an increased risk of mortality with somatropin therapy compared to the general population.
这个研究提出与普通人群相比使用生长激素治疗有增加死亡率的风险。
Elderly patients may be more sensitive to the actions of somatropin and may be more prone to develop adverse reactions.
老年患者对生长激素的作用会更敏感，而且会更易于出现不良反应。
In patients with GHD, central (secondary) hypothyroidism may first become evident or worsen during somatropin treatment.
患有GHD的患者，在采用生长激素治疗时，中央(次级)肾上腺机能衰退会首次变得明显或恶化。
Any child having onset of a limp or complaints of hip or knee pain during somatropin therapy should be carefully evaluated.
在生长激素治疗期间，出现跛行或诉说髋关节、膝关节疼痛的儿童，应谨慎评估。
Deaths have been reported in patients with Prader-Willi syndrome who are severely obese or have severe respiratory impairment and are treated with somatropin.
患严重肥胖或严重呼吸损伤的帕-魏二氏综合症，并使用生长激素治疗患者中，有死亡病例的报导。
Patients treated with somatropin should therefore have periodic thyroid function tests and thyroid hormone replacement therapy should be initiated or adjusted as needed.
因此采用生长激素治疗的患者应该进行周期性的甲状腺机能试验，如果需要，应启动或调节甲状腺激素替代治疗。
The European medicines Agency is starting a review of the safety of somatropin-containing medicines authorised centrally or by national procedures in the European Union (EU).
欧洲药监局将要以中心授权或者欧盟国家程序的形式来开始重审含有促生长激素药物的安全性。
Symptoms usually occurred within the first eight weeks after initiation of somatropin therapy and generally resolve after cessation of therapy or a reduction of the somatropin dose.
症状通常在启动生长激素治疗和停止治疗或生长激素剂量量减少后普遍起效的前八周出现。
Somatropin should not be used for growth promotion in pediatric patients with closed epiphysis or in patients with active proliferative or severe non - proliferative diabetic retinopathy.
生长激素不应用于儿科闭合骺患者，活性增生或严重非增生糖尿病视网膜病患者的生长促进。
Somatropin should not be used for growth promotion in pediatric patients with closed epiphysis or in patients with active proliferative or severe non - proliferative diabetic retinopathy.
生长激素不应用于儿科闭合骺患者，活性增生或严重非增生糖尿病视网膜病患者的生长促进。
应用推荐